Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
The Prader-Willi syndrome market is expected to grow steadily, driven by increasing disease awareness, improved diagnosis, and the development of novel targeted therapies such as WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance Therapeutics), HBS-102 (Harmony Biosciences), Setmelanotide (Rhythm Pharmaceuticals), and others.
LAS VEGAS, Oct. 12, 2026 /PRNewswire/ -- Recently published Prader-Willi Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Prader-Willi syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Prader-Willi Syndrome Market Summary
Discover the future of the Prader-Willi syndrome therapeutics market @ https://www.delveinsight.com/report-store/prader-willi-syndrome-market
Key Factors Driving the Growth of the Prader-Willi Syndrome Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the introduction of new therapies, particularly those with novel mechanisms of action or broader symptom coverage, may fragment prescriber preferences and intensify competition for patient share. This could pressure VYKAT XR's pricing flexibility, market uptake, or label expansion strategies, particularly if newer entrants demonstrate superior efficacy, safety, or convenience.
Prader-Willi Syndrome Market Analysis
Prader-Willi Syndrome Competitive Landscape
Some of the Prader-Willi syndrome medications under development include WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance Therapeutics), HBS-102 (Harmony Biosciences), Setmelanotide (Rhythm Pharmaceuticals), BMB-101 and BMB-105 (Bright Minds Biosciences), TNX-2900 (Tonix Pharmaceuticals), EPM301 (epm Therapeutics), and others.
Harmony Biosciences' WAKIX (pitolisant) is a selective histamine H₃ receptor antagonist/inverse agonist. The FDA has approved WAKIX for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. Although pitolisant is not currently approved for patients with Prader-Willi syndrome (PWS), it is being investigated as a potential treatment for the condition. The U.S. FDA has granted pitolisant Orphan Drug designation for the treatment of PWS.
Aardvark Therapeutics' ARD-101 is an investigational, orally administered small-molecule therapy being developed to address hyperphagia-related behaviors in patients with PWS. Its proposed mechanism involves stimulating gut-localized secretion of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), which may help reduce hyperphagia-related behaviors. ARD-101 is currently undergoing Phase III development in the HERO trial.
Palobiofarma's PBF-999 is an investigational, innovative phosphodiesterase 10 (PDE10) inhibitor developed by Palobiofarma. Preclinical studies have demonstrated potent and selective inhibition of the PDE10 enzyme, which plays an important role in regulating cyclic nucleotide levels, key signaling molecules involved in brain function. A Phase II clinical trial is currently evaluating PBF-999 in patients with PWS. The compound has previously been assessed in three clinical studies, where an appetite-suppressing effect was observed. Based on these findings, Palobiofarma has initiated a new clinical study to evaluate the safety and efficacy of PBF-999 in reducing hyperphagia among adults with PWS.
ConSynance Therapeutics' CSTI-500 is an investigational triple monoamine reuptake inhibitor (TRI) that targets serotonin, dopamine, and norepinephrine by inhibiting their respective transporters—SERT, DAT, and NET. These neurotransmitters play important roles in regulating behavior, appetite, feeding, and mood. CSTI-500 is an orally administered New Chemical Entity (NCE) designed to potentially restore key neurotransmitter balance in patients with PWS.
The anticipated launch of these emerging therapies are poised to transform the Prader-Willi syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Prader-Willi syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the medication for Prader-Willi syndrome @ Prader-Willi Syndrome Medication
Recent Developments in the Prader-Willi Syndrome Market
Prader-Willi Syndrome Epidemiology Segmentation
The Prader-Willi syndrome epidemiology section provides insights into the historical and current Prader-Willi syndrome patient pool and forecasted trends for the leading markets. In the US, roughly 70% of the PWS patients are children, whereas in Japan, the child population contributes to roughly 55% only.
The Prader-Willi syndrome treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Prader-Willi Syndrome Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Prader-Willi Syndrome Market Size in 2025
USD 700 Million
Key Prader-Willi Syndrome Companies
Harmony Biosciences, Aardvark Therapeutics, Palobiofarma, ConSynance Therapeutics, Rhythm Pharmaceuticals, Bright Minds Biosciences, Tonix Pharmaceuticals, epm Therapeutics, Soleno Therapeutics, and others
Key Prader-Willi Syndrome Therapies
WAKIX, ARD-101, PBF-999, CSTI-500, HBS-102, Setmelanotide, BMB-101, BMB-105, TNX-2900, EPM301, VYKAT XR, and others
Scope of the Prader-Willi Syndrome Market Report
Download the report to understand the recent developments in the Prader-Willi Syndrome treatment market @ Prader-Willi Syndrome Clinical Trials
Table of Contents
1
Prader-Willi Syndrome Market Key Insights
2
Prader-Willi Syndrome Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
PWS Market Overview at a Glance
6.1
Clinical Landscape Analysis (by Phase, Route of Administration, and Mechanism of Action)
6.2
Market Share by Therapies (%) Distribution of PWS in 2025 in the 7MM
6.3
Market Share by Therapies (%) Distribution of PWS in 2036 in the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Causes
7.4
Complications
7.5
Stages of PWS
7.6
Diagnosis
7.7
Differential Diagnosis
8
Treatment and Management
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationales
9.3
Total Prevalent Cases of PWS in the 7MM
9.4
Total Diagnosed Prevalent Cases of PWS in the 7MM
9.5
The United States
9.5.1
Total Prevalent Cases of PWS in the US
9.5.2
Total Diagnosed Prevalent Cases of PWS in the United States
9.5.3
Age-specific Cases of PWS in the United States
9.5.4
PWS Cases by Genetic Subtype in the US
9.6
EU4 and the UK
9.7
Japan
10
Patient Journey
11
Marketed Prader-Willi Syndrome Drugs
11.1
Key Competitors
11.2
VYKAT XR (diazoxide choline): Soleno Therapeutics
11.2.1
Product Description
11.2.2
Regulatory Milestone
11.2.3
Other Developmental Activity
11.2.4
Summary of Pivotal Trials
11.2.5
Clinical Developmental Activities
11.2.5.1
Clinical Trial Information
11.2.6
Safety and Efficacy
11.2.7
Analysts' Views
List to be continued in the full report….
12
Emerging Prader-Willi Syndrome Drugs
12.1
Key Competitors
12.2
WAKIX (pitolisant): Harmony Biosciences
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trial Information
12.2.4
Safety and Efficacy
12.2.5
Analysts' Views
12.3
ARD-101: Aardvark Therapeutics
12.4
PBF-999: Palobiofarma
List to be continued in the full report….
13
PWS Market: Seven Major Market Analysis
13.1
Key Findings
13.2
Prader-Willi Syndrome Market Outlook
13.3
Conjoint Analysis
13.4
Key Prader-Willi Syndrome Market Forecast Assumptions
13.5
Total Market Size of PWS in the 7MM
13.6
The United States Prader-Willi Syndrome Market Size
13.6.1
Total Market Size of PWS in the United States
13.6.2
Market Size of PWS by Therapies in the United States
13.7
EU4 and the UK Prader-Willi Syndrome Market Size
13.8
Japan Prader-Willi Syndrome Market Size
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Market Access and Reimbursement
17.1
The United States
17.2
EU4 and the UK
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement of PWS
18
Bibliography
19
Prader-Willi Syndrome Market Report Methodology
Related Reports
Prader-Willi Syndrome Clinical Trial Analysis
Prader-Willi Syndrome Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Prader-Willi syndrome companies, including Harmony Biosciences, ACADIA Pharmaceuticals, Jazz Pharmaceuticals, Aardvark Therapeutics, ConSynance Therapeutics, and others.
Obesity Market
Obesity Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.
Angelman Syndrome Market
Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Angelman syndrome companies, including GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and others.
Fragile X Syndrome Market
Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Fragile X syndrome companies, including Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP